MX2015002399A - Derivados de oxazolidinona 3,4-disustituidos y su uso como inhibidores del canal de potasio activado con calcio. - Google Patents
Derivados de oxazolidinona 3,4-disustituidos y su uso como inhibidores del canal de potasio activado con calcio.Info
- Publication number
- MX2015002399A MX2015002399A MX2015002399A MX2015002399A MX2015002399A MX 2015002399 A MX2015002399 A MX 2015002399A MX 2015002399 A MX2015002399 A MX 2015002399A MX 2015002399 A MX2015002399 A MX 2015002399A MX 2015002399 A MX2015002399 A MX 2015002399A
- Authority
- MX
- Mexico
- Prior art keywords
- phenyl
- compound according
- alkyl
- oxo
- fluoro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12190319 | 2012-10-29 | ||
| PCT/EP2013/072361 WO2014067861A1 (en) | 2012-10-29 | 2013-10-25 | 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015002399A true MX2015002399A (es) | 2015-06-10 |
Family
ID=47143594
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015002399A MX2015002399A (es) | 2012-10-29 | 2013-10-25 | Derivados de oxazolidinona 3,4-disustituidos y su uso como inhibidores del canal de potasio activado con calcio. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US9611232B2 (enExample) |
| EP (1) | EP2912034B1 (enExample) |
| JP (1) | JP6216385B2 (enExample) |
| KR (1) | KR20150075091A (enExample) |
| CN (1) | CN104781256B (enExample) |
| AR (1) | AR093168A1 (enExample) |
| AU (1) | AU2013339607A1 (enExample) |
| BR (1) | BR112015003996A2 (enExample) |
| CA (1) | CA2879249A1 (enExample) |
| CL (1) | CL2015000906A1 (enExample) |
| CO (1) | CO7170170A2 (enExample) |
| CR (1) | CR20150159A (enExample) |
| EA (1) | EA026161B1 (enExample) |
| IL (1) | IL237331A0 (enExample) |
| IN (1) | IN2015DN00961A (enExample) |
| MA (1) | MA38135B1 (enExample) |
| MX (1) | MX2015002399A (enExample) |
| PE (1) | PE20150775A1 (enExample) |
| PH (1) | PH12015500292A1 (enExample) |
| SG (1) | SG11201500585XA (enExample) |
| TW (1) | TW201422596A (enExample) |
| UA (1) | UA114649C2 (enExample) |
| WO (1) | WO2014067861A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102047502B1 (ko) * | 2016-06-20 | 2019-11-22 | 셀라이온바이오메드 주식회사 | 포타슘 채널 단백질을 이용한 암 진단용 조성물 |
| KR102865950B1 (ko) | 2019-03-22 | 2025-09-30 | 사니오나 에이/에스 | 신규의 칼륨 채널 억제제 |
| AU2021350333A1 (en) | 2020-09-22 | 2023-05-04 | Saniona A/S | Novel potassium channel inhibitors |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2538424C2 (de) * | 1975-08-29 | 1983-01-05 | Nordmark-Werke Gmbh, 2000 Hamburg | 4-substituierte 5-Phenyl-oxazolidon-(2)- Verbindungen und ein diese enthaltendes pharmazeutisches Präparat |
| ES2000907A6 (es) * | 1985-09-09 | 1988-03-16 | Otsuka Pharma Co Ltd | Procedimiento de preparar compuestos 2-oxaisocefen microbiologicamente activos |
| KR930703262A (ko) * | 1990-11-06 | 1993-11-29 | 스튜어트 알. 슈터 | 이미다졸리디논 화합물 |
| DE4439846A1 (de) * | 1994-11-08 | 1996-05-09 | Merck Patent Gmbh | Adhäsionsrezeptor-Antagonisten |
| WO1997031892A1 (fr) * | 1996-03-01 | 1997-09-04 | Sankyo Company, Limited | Derives d'acide hydroxamique |
| EP1144387A1 (en) * | 1998-12-04 | 2001-10-17 | Neurosearch A/S | New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| JP3966693B2 (ja) * | 2000-01-20 | 2007-08-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 含窒素環化合物およびそれらを含んでなる医薬組成物 |
| IL150651A0 (en) * | 2000-01-20 | 2003-02-12 | Eisai Co Ltd | Nitrogen-containing cyclic compound and pharmaceutical compositions containing the same |
| AU2002221827A1 (en) * | 2000-11-22 | 2002-06-03 | Bayer Aktiengesellschaft | Novel lactame-substituted pyrazolopyridine derivatives |
| EP1781635B1 (en) | 2004-07-29 | 2012-06-13 | Merck Sharp & Dohme Corp. | Potassium channel inhibitors |
| DE102004060229A1 (de) * | 2004-12-15 | 2006-06-29 | Sanofi-Aventis Deutschland Gmbh | Neue zyklische Harnstoffe als Inhibitoren von Metallproteasen |
| US7378530B2 (en) * | 2005-02-22 | 2008-05-27 | Nereus Pharmaceuticals, Inc. | Anti-cancer and anti-microbial 5-membered heterocyclic compounds |
| US20100056637A1 (en) | 2005-12-20 | 2010-03-04 | Icagen, Inc. | Treatment methods using triaryl methane compounds |
| WO2007109098A2 (en) * | 2006-03-16 | 2007-09-27 | Azevan Pharmaceuticals, Inc. | HYDROXY AND KETO-SUBSTITUTED β-LACTAMYL ALKANEDIOIC ACIDS |
| TW201026708A (en) | 2008-12-12 | 2010-07-16 | Solvay Pharm Bv | Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers |
| WO2010123997A1 (en) * | 2009-04-22 | 2010-10-28 | Achaogen, Inc. | Carbacephem beta-lactam antibiotics |
-
2013
- 2013-10-25 EA EA201590729A patent/EA026161B1/ru not_active IP Right Cessation
- 2013-10-25 UA UAA201504977A patent/UA114649C2/uk unknown
- 2013-10-25 BR BR112015003996A patent/BR112015003996A2/pt not_active IP Right Cessation
- 2013-10-25 MX MX2015002399A patent/MX2015002399A/es unknown
- 2013-10-25 CA CA2879249A patent/CA2879249A1/en not_active Abandoned
- 2013-10-25 SG SG11201500585XA patent/SG11201500585XA/en unknown
- 2013-10-25 AU AU2013339607A patent/AU2013339607A1/en not_active Abandoned
- 2013-10-25 CN CN201380056503.4A patent/CN104781256B/zh not_active Expired - Fee Related
- 2013-10-25 KR KR1020157011024A patent/KR20150075091A/ko not_active Withdrawn
- 2013-10-25 EP EP13783333.1A patent/EP2912034B1/en not_active Not-in-force
- 2013-10-25 PE PE2015000296A patent/PE20150775A1/es not_active Application Discontinuation
- 2013-10-25 JP JP2015538458A patent/JP6216385B2/ja not_active Expired - Fee Related
- 2013-10-25 IN IN961DEN2015 patent/IN2015DN00961A/en unknown
- 2013-10-25 MA MA38135A patent/MA38135B1/fr unknown
- 2013-10-25 WO PCT/EP2013/072361 patent/WO2014067861A1/en not_active Ceased
- 2013-10-28 AR ARP130103922A patent/AR093168A1/es unknown
- 2013-10-28 TW TW102138950A patent/TW201422596A/zh unknown
-
2015
- 2015-01-16 CO CO15008510A patent/CO7170170A2/es unknown
- 2015-02-10 PH PH12015500292A patent/PH12015500292A1/en unknown
- 2015-02-19 IL IL237331A patent/IL237331A0/en unknown
- 2015-03-20 CR CR20150159A patent/CR20150159A/es unknown
- 2015-04-10 CL CL2015000906A patent/CL2015000906A1/es unknown
- 2015-04-29 US US14/699,144 patent/US9611232B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150075091A (ko) | 2015-07-02 |
| EP2912034B1 (en) | 2017-05-31 |
| CL2015000906A1 (es) | 2015-09-11 |
| TW201422596A (zh) | 2014-06-16 |
| MA38135A2 (fr) | 2016-11-30 |
| EP2912034A1 (en) | 2015-09-02 |
| SG11201500585XA (en) | 2015-04-29 |
| AR093168A1 (es) | 2015-05-20 |
| US20150246894A1 (en) | 2015-09-03 |
| JP2015535231A (ja) | 2015-12-10 |
| IL237331A0 (en) | 2015-04-30 |
| PE20150775A1 (es) | 2015-05-21 |
| HK1207632A1 (en) | 2016-02-05 |
| US9611232B2 (en) | 2017-04-04 |
| PH12015500292A1 (en) | 2015-04-20 |
| EA201590729A1 (ru) | 2015-07-30 |
| JP6216385B2 (ja) | 2017-10-18 |
| CR20150159A (es) | 2015-04-30 |
| AU2013339607A1 (en) | 2015-02-05 |
| UA114649C2 (uk) | 2017-07-10 |
| EA026161B1 (ru) | 2017-03-31 |
| IN2015DN00961A (enExample) | 2015-06-12 |
| CN104781256A (zh) | 2015-07-15 |
| WO2014067861A1 (en) | 2014-05-08 |
| CO7170170A2 (es) | 2015-01-28 |
| MA38135B1 (fr) | 2018-11-30 |
| CN104781256B (zh) | 2017-09-29 |
| BR112015003996A2 (pt) | 2017-07-04 |
| CA2879249A1 (en) | 2014-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100814599B1 (ko) | 신경퇴행성 장애 치료용 이미다졸 화합물 | |
| US20100113465A1 (en) | 7-azaspiro[3.5]nonane-7-carboxamide compounds | |
| JP2009519929A (ja) | オキサゾリジノン化合物及び代謝型グルタミン酸レセプター増強剤としてのそれらの使用 | |
| TW200911254A (en) | Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators-842 | |
| JP2002542229A (ja) | カルバミン酸誘導体および代謝型グルタミン酸受容体配位子としてその使用 | |
| EP0757685B1 (en) | Novel acyclic and cyclic amides as neurotransmitter release enhancers | |
| US12391664B2 (en) | GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor | |
| MXPA06013603A (es) | Piridin-4-il-etinil-imidazoles y pirazoles como antagonistas del receptor mglu5. | |
| CN102015682A (zh) | 作为肾素抑制剂的3,4-取代的哌啶衍生物 | |
| KR20130143141A (ko) | 피라졸리딘-3-온 유도체 | |
| TWI527808B (zh) | 乙炔基衍生物 | |
| US9611232B2 (en) | Oxazolidinone and imidazolidinone compounds | |
| KR100401314B1 (ko) | 벤즈이미다졸 유도체 및 그의 약학적으로 허용되는 염 | |
| JP2021500416A (ja) | 疼痛及び疼痛関連状態を治療するための新規アルコキシアミノ誘導体 | |
| JP2007277230A (ja) | 医薬組成物 | |
| US8410135B2 (en) | 4,5 dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators | |
| HK1207632B (en) | 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel | |
| CA2688208A1 (en) | 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators | |
| HK1099756B (en) | Imidazole compounds for the treatment of neurodegenerative disorders | |
| CN101939300A (zh) | 作为大麻素cb1受体调节剂的4,5-二氢-(1h)-吡唑衍生物 |